Summary The effects of several members of the family of lamellarins, polyaromatic alkaloids isolated from tunicates belonging to the genus Didemnwn, on the growth of several tumour cell lines and on P-glycoprotein (P-gp)-mediated multidrug resistance (MDR), were investigated. Cytotoxicity experiments of lamellarins were performed on a panel of tumour cell lines, including two multidrug-resistant cell lines. Some lamellarins showed good anti-tumour activity, with similar levels of cytotoxicity against both the resistant and their corresponding parental cell lines. Two lamellarins displayed a high potency against lung carcinoma cells. Studies of the resistance modifier activity of the different lamellarins at non-toxic concentrations were also carried out in cells exhibiting MDR, and lamellarin I was selected for the highest chemosensitising activity. At non-toxic doses, verapamil and lamellarin I effectively increased the cytotoxicity of doxorubicin, vinblastine and daunorubicin in a concentration-dependent manner in multidrug-resistant cells, but the potency of lamellarin I as a MDR modulator was 9-to 16-fold higher than that of verapamil. In vitro measurements of rhodamine 123 accumulation in the multidrug-resistant Lo Vo/Dx cells suggest that lamellarin I reverses MDR by directly inhibiting the P-gp-mediated drug efflux. This work underscores the possibility of using these marine-derived compounds as a potential new source of anti-tumoral drugs active on resistant cells as well as of non-toxic modulators of the MDR phenotype.
Development of drug resistance is one of the major obstacles to effective cancer chemotherapy. Clinical resistance to anticancer agents occurs at the time of presentation as well as during the course of treatment and at relapse.
Although a number of different drug resistance mechanisms has been identified in the laboratory, perhaps the most intensively studied has been multidrug resistance (MDR), which is characterised by a failure to respond to a variety of chemotherapeutic agents that do not share a common structure or a common intracellular target. It is now well established that the major mechanism of MDR in mammalian cells involves the overexpression of a 170 kDa plasma membrane glycoprotein (P-gp), encoded in humans by the gene MDRJ. P-gp belongs to the ATP-binding cassette superfamily of transporter proteins, and is thought to function as a broad-substrate ATP-dependent pump, which exports drugs out of mammalian cells, lowering the intracellular drug concentration below the cytotoxic threshold (For recent reviews see Gottesman and Pastan, 1993; Patel and Rothenberg, 1994) .
Many studies have attempted to assess the contribution of P-gp to clinical outcome. Overexpression of the MDR] gene has been found in tumours derived from tissues that normally express this gene, as well as in untreated cancers derived from tissues that do not express MDRI at detectable levels (Nooter and Herweijer, 1991) . In some cases, correlations have been made between expression of P-gp and poor prognosis, which included failure to respond to chemotherapy. Increased expression of MDR] is often seen in tumours treated with chemotherapy that have relapsed during the course of, or after chemotherapy (Arceci, 1993) . Moreover, it has recently been suggested that the process of malignant transformation per se can activate the expression of the MDRI gene (Benchimol and Ling, 1994) .
A goal of current cancer research is to find ways to overcome or circumvent drug resistance due to expression of P-gp. Attempts to overcome the problem of MDR involve two main approaches: the first one includes the search for clinically useful drugs that retain relatively good activity on multidrug-resistant cells. The second major approach to the circumvention of MDR is the use of resistance modifiers, that is, agents that are able to reduce the degree of drug resistance in multidrug-resistant cells by interfering with the pump's drug efflux function. These drugs, also referred to as MDR reversal agents, inhibit the efflux of P-gp substrate drugs out of cells in vitro, and result in the 'resensitisation' of the resistant malignant cell.
Since the early observation of Tsuruo et al. (1981) that non-cytotoxic doses of verapamil could restore sensitivity to vinca alkaloids in multidrug-resistant cells, a large number of resistance modifier agents (RMAs) has been found, including calcium-channel blockers (Tsuruo et al., 1983) , calmodulin inhibitors (Ganapathi and Grabowski, 1983) , tamoxifen and its analogues (Ramu et al., 1984) , cyclosporins (Twentyman, 1988) and protein kinase inhibitors (Miyamoto et al., 1993) . These agents were originally developed for pharmacological effects other than circumvention of MDR, and therefore dose escalation in MDR reversal studies has often resulted in serious toxicities. Existing problems associated with their use as RMAs include the inability to achieve clinically effective plasma concentrations sufficient to inhibit P-gp activity, their short half-life and rapid clearance, and the unacceptable toxicities of these drugs when used at levels effective in sensitising cancer cells (Ozols et al., 1987; Miller et al., 1988; Pennock et al., 1991) . Although several agents that are much more effective at sensitising multidrug-resistant cells in vitro than compounds previously examined as modulators have been described, such as the non-immunosuppressive cyclosporin A analogue PSC-833 (Twentyman and Bleehen, 1991) and the cyclopeptolide SDZ 280-446 (Loor et al., 1992) (Grandi et al., 1986 (Grandi et al., , 1987 One day before experimental use the culture medium of the multidrug-resistant cell lines was removed, and the cells were grown in drug-free medium. The AUXB1 cell line, which is auxotrophic for glycine, adenosine and thymidine (Thomson and Baker, 1973; McBurney and Whitmore, 1974 ) is the wild-type CHO (chinese hamster ovary) line from which CCHRC5 (showing a relative resistance to doxorubicin of 25-fold in comparison with its parental cell line) was selected by Ling et al. (Ling, 1982; Kartner et al., 1985) . Both CHO cell lines were kindly provided by Dr RC Hughes Jr. (Roswell Park Cancer Institute, Buffalo, NY, USA) and were maintained (37°C, 5% carbon dioxide in a humid atmosphere) in logarithmic phase of growth in Eagle's minimum essential medium with Earle's balanced salts, 0.01 M sodium bicarbonate, 1% non- Figure 1 Chemical structure of the lamellarins tested. (Biedler, 1994 Although it is difficult to find structural features that are common to a large number of chemosensitisers. it has been suggested that RMAs are hydrophobic. contain two or more planar aromatic rings. and a tertiary nitrogen (Zamora et al.. 1988; Pearce et al., 1989) . The structure of lamellarins fits this proffle.
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In conclusion, the potential use of lamellarins for the treatment of multidrug-resistant tumours may follow two different approaches: at toxic concentrations they can be used as antitumoral drugs active on the resistant tumours. and at non-toxic concentrations they can be employed as reversing agents. that is. compounds able to potentiate the cytotoxic activity of other antitumoral drugs such as doxorubicin. 
